Abstract
PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P=0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P
Original language | English |
---|---|
Pages (from-to) | 927-933 |
Number of pages | 7 |
Journal | Journal of Cellular Physiology |
Volume | 227 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 2012 |
ASJC Scopus subject areas
- Clinical Biochemistry
- Cell Biology
- Physiology